Although nasal hyperreactivity (NHR) is a common feature in patients suffering from allergic and nonallergic rhinitis, it is widely neglected during history taking, underdiagnosed in the majority of patients with rhinitis and rhinosinusitis, not considered as an outcome parameter in clinical trials on novel treatments for rhinitis and rhinosinusitis, and no target for routine treatment. In contrast to the simple nature of diagnosing NHR by a history of nasal symptoms induced by nonspecific exogenous and/or endogenous triggers, quantification is hardly performed in routine clinic given the lack of a simple tool for its diagnosis. of NAR. In this recent publication, 5 the pathophysiology of IR was studied rather than the prevalence and the inclusion criteria for IR were stricter than for NAR which explains the lower patient
| INTRODUCTION
Nasal hyperreactivity (NHR) is defined as "the induction of one or more nasal symptoms like rhinorrhea, sneezing/itch, or obstruction upon encounter of environmental stimuli, such as cigarette smoke, temperature/humidity changes, strong odors/fragrances, and other irritants". 1 NHR can be found in all types of rhinitis, varying from infectious rhinitis like common cold to both nonallergic rhinitis (NAR) and allergic rhinitis (AR). 2 However, limited data on the prevalence of NHR in the different phenotypes of rhinitis are available. Segboer et al 2 reported a prevalence of NHR of 66.9% in NAR patients and 63.4% in AR patients in relatively large cohorts of 408 and 585 patients, respectively ( Figure 1 ). The latter study 2 was mainly questionnaire based, although a subgroup of the included patients (18 AR and 21 NAR patients) also underwent a cold dry air (CDA) nasal provocation test which confirmed in an objective way the presence of NHR in all patients who reported NHR in the questionnaires and not in healthy controls. So far, only one study 3 reported on simultaneous subjective (questionnaire-based) and objective (cold dry air nasal provocation test) ways to diagnose NHR and they found a good correlation between both. These observations on the NHR prevalence were in line with previous questionnaire-based investigations by Lindberg et al 4 (60% in both NAR and AR). Recently, our research group 5 demonstrated a questionnaire-based prevalence of NHR of 58% in 33 patients with idiopathic rhinitis (IR), a subgroup of NAR. In this recent publication, 5 the pathophysiology of IR was studied rather than the prevalence and the inclusion criteria for IR were stricter than for NAR which explains the lower patient numbers ( Figure 1 ). For infectious rhinitis, postviral NHR is documented in up to 80%, which is similar to the prevalence of postviral bronchial hyperreactivity in the lower airways 6,7 ( Figure 1 ).
Up until now, no clear difference between chemical triggers like cigarette smoke, fragrances, cleaning agents (irritants), and physical triggers like temperature changes, exercise, emotional stress, and humidity could be observed in NAR and AR patients, indicating that NHR is a more general "outcome" of disturbed nasal mucosa/diseased mucosa of the upper respiratory tract. 2 The same applies to bronchial hyperreactivity, a common and aspecific symptom of diseased lower airway mucosa in asthma and chronic obstructive pulmonary disease (COPD) patients, without exclusive sensitivity to physical or chemical stimuli. 8 Moreover, mucosal hyperreactivity in general has been suggested to be found in the majority of patients with uncontrolled disease of both upper (rhinitis) and lower (asthma) airways. 9 The purpose of this review was to provide a concise overview of how NHR can be diagnosed, the underlying pathophysiological mechanisms, and treatment options.
| DIAGNOSTIC TESTS
Although the prevalence of NHR is around 60%-70% in all subgroups of rhinitis, it is often neglected in clinical practice due to the lack of a good diagnostic test. Although many nasal provocation tests are described during the past decades, none of these tests could be implemented in daily practice. [10] [11] [12] [13] [14] [15] [16] The main reason for this disuse is that none of the provocation tests have a sufficiently high sensitivity and specificity in combination with a protocol that is patient-and investigator-friendly (Table 1) . The term patient-friendly is applied when little cooperation from the patients is required and when the patient is not exposed to uncomfortable examinations such as nasal lavages or irritating stimuli like capsaicin. The term investigator-friendly is mainly focusing on the fact that the protocol is not time-consuming (15-20 minutes, comparable with the time needed to perform a skin prick test) and easy to apply without the need of extensive equipment.
Nasal provocations with hyperosmolar solutions, 10, 11 histamine, 7, 13 cold dry air (CDA), [12] [13] [14] 16 and capsaicin 15, 17 are described to diagnose NHR, mainly in research settings. Amongst those, CDA turned out to be the most physiological, safe, and tolerable stimulus for the nasal mucosa, as well as the most patient-friendly in terms of application (nasal inhalation versus nasal instillation) ( Table 1) .
Nasal lavages should be avoided in provocation tests to diagnose NHR as they can influence the outcome due to mechanical stimulation of the nasal mucosa which subsequently can induce symptoms.
Additionally, high patient cooperation is warranted for a good nasal lavage and therefore it is more difficult to obtain. Braat et al 13 demonstrated that CDA provocations were superior to nasal histamine provocations in discriminating IR patients from healthy 
controls. Sensitivity for CDA provocation was 87% compared with 100% for histamine provocation, but specificity was 71% for CDA and 0% for histamine provocation test. 13 Additionally, the reproducibility of the CDA provocation for both nasal patency and mucus production was very good. 13 However, the protocol used in the latter study is very time-consuming (> 45 minutes) and probably therefore not suitable for routine use in daily practice. For this reason, a shorter protocol was tested by Van Gerven et al 16 with a sensitivity of 66.7% and specificity of 100% to detect NHR in both AR and IR.
In this study, patients were exposed to cold (< À10°C), dry (< 10% humidity) air for 15 minutes and a decrease in peak nasal inspiratory flow (PNIF) of 20% or more was chosen as the predefined cutoff point to evaluate the presence of NHR. This cutoff point of 20%
was based on the FEV1 decrease of 20% after exercise challenge test, histamine provocation test, or specific inhalation challenge test, performed for diagnosing bronchial hyperreactivity in lower airway pathology. Although the short CDA protocol seems attractive, some major limitations need to be addressed in further research: 1 the election of a decrease of 20% in PNIF was not supported by studies performed with both positive and negative control subjects, and based on appropriate statistic methods (receiver operating characteristic curves); 2 the reproducibility was not evaluated; and 3 higher patient numbers are warranted to really validate this technique.
There is now growing consensus about the usefulness of such a technique as NHR often remains undiagnosed and cannot be taken into account in trials evaluating the effects of medical treatment for rhinitis.
18,19

| PATHOPHYSIOLOGY OF NASAL HYPERREACTIVITY
The pathophysiology of NHR or nasal "hyperresponsiveness" is believed to be the consequence of "alterations" in the nasal innervation. 18 The neural regulation of the upper airways is complex and consists of a number of interacting nervous systems ( Figure 2 ). Basal neural regulation in the upper airways is maintained by the sympathetic (adrenergic) and the parasympathetic (cholinergic) nervous systems, which regulate epithelial, vascular, and glandular processes. 20 The sympathetic nerve fibers innervate mainly the vascular structures and to a lesser extent the secretory glands, where they release norepinephrine and neuropeptide Y (NPY) to cause predominantly vasoconstriction and to decrease in nasal secretion. 21 Parasympathetic fibers innervate both the blood vessels and the exocrine (seromucous and serous) glands of the nasal mucosa, which appears to be more densely innervated. These nerve fibers predominantly release acetylcholine and neuropeptide transmitters such as vasoactive intestinal peptide (VIP). Local release of VIP and acetylcholine increases the production of nasal secretion and induces vasorelaxation leading to nasal congestion. VIP mainly acts through binding VIP receptor type 1 (VPAC1) and VPAC2 receptors leading to glandular secretion. 20 Under normal conditions, the sympathetic nervous system is dominant ensuring vascular tone.
Some NAR endotypes are based on a relatively simple regulatory disorder of this efferent nasal nervous system. Rhinitis of the elderly seems to be a dysregulation of the parasympathetic/sympathetic neural balance caused by degeneration of the sympathetic system in favor of the parasympathetic pathway. Hence, rhinitis of the elderly is mainly characterized by symptoms such as watery rhinorrhea, which can be treated with the anticholinergic drug ipratropium bromide. 22 Also in rhinitis medicamentosa, dysregulation of the adrenergic receptors in the nasal mucosa results in a relative increase in the parasympathetic drive, leading to significant nasal obstruction with/ without rhinorrhea. 23 In many other phenotypes of rhinitis, the pathophysiology is more complex and involves alterations in the afferent nervous system. Several decades ago, the presence of intraepithelial and perivascular nonadrenergic noncholinergic (NANC) sensory nerve fibers was demonstrated in the human nasal mucosa. 24 Nowadays, it is generally accepted that these afferent sensory nerves play a crucial role in nasal homeostasis and may even cause so called "neurogenic inflammation" under pathological conditions. 20 Mainly unmyelinated sensory C-fibers contain various neuropeptides including substance P (SP), 25 calcitonin gene-related peptide (CGRP), 26 and TRPA1. 27, 28 Cold temperatures or other environmental factors (TRPM8) can also directly activate (antidromic) the afferent nerves in the nasal mucosa ( Figure 1 ). 29 In physiological condition, these sensory (NANC) nerve fibers play, in conjunction with the parasympathetic nerve fibers, an essential role in protective nasal clearing reflexes (orthodromic) such as sneezing, mucus production, and congestion in response to noxious stimuli ( Figure 2 ). 28 Several studies 27, 30 point out toward a role of this afferent neurogenic system in occupational and idiopathic airway disease, and more specifically in irritant-induced symptoms which are by definition activators of the trigeminal nerve endings.
Indeed, our recent data 31 strongly support the involvement of the TRPV1 and TRPA1 nociceptor activation in the pathophysiology of IR, in which NHR is a key feature. We could nicely document an increased nasal chemical sensitivity to the TRPA1 and TRPV1 agonist allyl isothiocyanate (AITC) (= mustard oil) in IR patients with a clear decrease in both the sensitivity to AITC and NHR after capsaicin treatment (see further). 5 The baseline overexpression of TRPV1 in combination with the increased chemical sensitivity in IR patients illustrates the crucial role of the TRPV1-SP nociceptive signaling pathway in the pathophysiology of IR, both structurally and functionally as previously suggested (Figure 3 ). 31 The trigger that causes upregulation of TRPV1/A1 is unknown so far. Recently, Abdullah et al 32 showed that TRPV1/A1 and TRPM8 were upregulated on neuronal cells after rhinovirus 16 infection. However, in our IR population 5, 31 and in the IR population described by Van Rijswijk et al, 33 no signs of infection were present throughout the study protocol, but this observation can explain postinfectious NHR. Bradykinin is also known to upregulate TRPV1 expression which can explain the NHR present in AR. 34 A similar association was found in patients with irritable bowel syndrome and neurogenic bladder overactivity, showing enhanced TRPV1 expression and hypersensitivity of the bowel and bladder, respectively. [35] [36] [37] In the lower airways, a recent publication 38 showed that patients with severe asthma had increased 
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F I G U R E 2 Schematic overview of the nasal innervation. Both the classical orthodromic and antidromic pathway are depicted. Activation of the orthodromic pathway: a stimulus (irritant, change in temperature, etc.) comes in during inhalation and stimulates TRP channels, present on the afferent nerves in the nasal epithelium, the signal is than transmitted to the trigeminal system in the brain and efferent fiber activation results in mucus production and vasodilation (parasympathetic) or vasoconstriction (sympathetic). Activation of the antidromic pathway: upon strong stimulation of TRP channels, afferent nerve fibers can release immediately neuropeptides, present in those nerves like substance P (SP), nerve growth factor (NGF), neurokinins A and B (NKA/B), and calcitonin gene-related peptide (CGRP) with consequently direct activation of mucus producing cells and vasodilation. Pictograms: cold temperature (snowflake)) is a TRPM8 activator, allyl-isothiocyanate (mustard oil) is a TRPA1/V1 activator, and capsaicin (red pepper) is a TRPV1 agonist VAN GERVEN ET AL.
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TJs are apically located multiprotein complexes consisting of transmembrane proteins like occludin, claudins, and tricellulin, which are connected to the cytoskeleton via scaffold adaptor proteins such as zonula occludens, regulating transport of water, ions, and certain macromolecules. 43 When the epithelial barrier is disrupted, environmental and microbial factors might easily gain access to the submucosal region, triggering strong innate immune responses. Indeed, barrier dysfunction as part of the pathology of different respiratory inflammatory diseases has been described in literature. 42 Recently, our research group observed an impaired nasal epithelial barrier in patients with house-dust mite-induced AR, due to the loss of occludin and ZO-1 expression. 44 Moreover, treatment with intranasal steroids stimulated the expression of occludin and ZO-1 restoring epithelial barrier integrity again in AR patients. The question remains whether inflammation drives barrier disruption or whether it is a defective barrier that leads to sensitization and aberrant inflammatory responses. Strikingly, we observed no epithelial barrier defects in our strictly selected IR patients compared to AR patients. 45 Different underlying mechanisms responsible for the induction of nasal symptoms, that is neurogenic inflammation in IR and IgE-mediated inflammation in AR, are probably responsible for these observations.
Histologically, NHR in IR has been shown to be associated with increased expression of the neuropeptides CGRP and SP in periglandular nerve fibers, which is considered a sign of neuronal hyperactivity. 46 SP levels in nasal secretions of IR patients were significantly higher compared to levels measured in controls. 31 
| TREATMEN T OF NASAL HYPERR EACTIVITY
Although NHR is present in many nasal conditions, no uniform treatment is described in literature. In clinical practice, NHR associated with AR is treated according to the ARIA guidelines, 50 whereas NHR in NAR and IR is often treated with intranasal corticosteroids with mixed results. [51] [52] [53] Unfortunately, NHR was considered as primary endpoint in only 1 randomized placebo-controlled trial. 33 This "gap" in literature can be explained by the lack of a good diagnostic tool to evaluate NHR as an objective endpoint. Van Rijswijk et al 33 showed decreased NHR after nasal capsaicin treatment in IR patients. Capsaicin is the that given the fact that many other options do not work well in IR patients, capsaicin is a reasonable option to try under physician supervision. Capsaicin nasal treatment has not been shown to be effective in AR, where the IgE-mediated pathway is predominant and so far no overexpression of TRPV1 could be demonstrated. 55 In spite of these convincing data, capsaicin is not widely used to treat NHR. 54 The main reasons are probably the facts that treatment with capsaicin is time-consuming (5 hours in hospital setting) and financially not interesting for ENT physicians and the pharmaceutical industry. So far, one TRPV1 antagonist (SB-705498) was developed by GlaxoSmithKline for intranasal use and tested in healthy controls with preliminary results. 17 The antagonist showed an appropriate safety and pharmacokinetic profile for development in humans, but the potential impact of intranasal SB-705498 on rhinitis symptoms needs further evaluation. A small trial on the effect of SB-705498 (3% nasal cream) on histamine-and cowhage challenge-induced pruritus was negative in (human) healthy controls. 56 The negative outcome of this study can be easily explained by (i) the fact that this trial was performed in healthy controls which are known to have no overexpression of the TRPV1-SP pathway and (ii) the fact that nasal capsaicin treatment of 0.1 mmol/L targets not only TRPV1, but also probably all TRP channels that are co-expressed on the nasal afferent nerves (like TRPA1).
Since many years, the use of azelastine has been found to be effective in NAR patients, 57 but only recently, azelastine has been demonstrated to exhibit TRPV1 channel activity through the modulation of Ca 2+ signaling on sensory neurons and in nasal epithelial cells. 58 Roles of antimuscarinic agents such as tiotropium in NAR have been suggested by associations of muscarinic cholinergic receptors with TRPV1. hyperreactivity, the impact of NHR in rhinitis and CRS, and effective treatments for NHR in a daily practice. Identifying or measuring the molecular mediators responsible for NHR will be essential for defining new therapeutic interventions.
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